Delving into Allegations
Investors in Ovid Therapeutics Inc. have found themselves at the mercy of potential legal turbulence. The Schall Law Firm, renowned for its crusades in shareholder rights litigation, has placed the Company under its scrutinizing lens. Allegations of stock law violations are now a looming shadow over Ovid’s reputation.
Unraveling the Story
The heart of the investigation beats to the tune of potential deceit. Questions arise regarding the veracity of statements issued by the Company. The storm gathered momentum post Ovid’s press release on March 30, 2021. Takeda Pharmaceutical Company Limited took the reins for the global development and commercialization rights of soticlestat (TAK-935/OV935). However, the narrative took a turn on June 17, 2024, concerning Takeda’s Skyline study in Dravet syndrome and Skyway study in Lennox-Gastaut syndrome.
Opportunity Knocks
Shareholders who have weathered financial losses can now choose to embark on a journey towards potential reparation. The Schall Law Firm extends an invitation to impacted parties. A simple click stands between shareholders and the prospect of participation, a gateway to holding accountability.
Seeking Justice
Brian Schall is the beckoning light, guiding those lost in the legal labyrinth to free consultations. His office, a bastion at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, awaits the afflicted shareholders. Alternatively, a digital lifeboat in the form of the firm’s website or an email line is there for those who seek refuge with the Schall Law Firm.
Standing Strong
The Schall Law Firm, a global sanctuary for investors, specializes in unraveling the intricacies of securities class action lawsuits and shareholder rights litigation. Their mission stands firm as they navigate the choppy waters of potential legal malpractice.